On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion.
What changes if the standard account of Sequence verification is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.
Working through the consequences rather than the evidence, since others here are better placed on the evidence.
AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.
That is my reading. Someone else read the same page differently and was reasonable.
Building on post #2 rather than restating it.
Anyone submitting an unusual compound for testing should tell the laboratory what it is rather than what it is sold as. Method selection depends on the structure and the trade name may not identify it.
Worth checking against a second source before it gets quoted onward.
The opening post put the caveat in the right place and I want to underline it.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.
Post #2 answers the question as asked. The question underneath it is different.
A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry.
Where a compound has a legitimate pharmaceutical form somewhere in the world, the labelling for that form is usually the single most useful document available and is almost never consulted here.
Adding a data point of agreement rather than a data point.
Post #4 and I disagree about the size of the effect, not about the direction.
An update on my earlier Sequence verification post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Post #6 is right about the mechanism and I think understates the practical bit.
Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end of that range a specific compound sits at before anything else.
The right answer here may simply be that it has not been measured.
Coming back to post #8, because the follow-up matters more than the original answer.
Where I would push back on the Sequence verification consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
Everything in post #8 holds. The case it does not cover is the one I have.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
That holds under the stated conditions and I have stated them.
The practical version of Sequence verification is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
For any compound without a widely available reference standard, retention-time comparisons across laboratories are close to meaningless. Only a mass result travels.
Agreed on all of that, and I have nothing to add to it.
Careful with the language on Sequence verification. "Not detected" and "not present" are different findings and the first is a statement about the method.
Sequence verification: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.
That holds for the case as described. Change the assumptions and it may not.
Taking post #15 at face value and following it one step further.
The thing about Sequence verification that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
Adding the measurement that post #19 says would settle it.
Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.
On reflection I would soften that slightly.
I will take the caveat as seriously as the claim, which is the point of putting it there.
When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.
Adding the measurement that post #20 says would settle it.
Solubility varies far more across this subcategory than within the incretins. A compound that needs a specific diluent or a specific pH is not being difficult; it has a solubility profile and the supplier should state it.
The general answer and the answer for your case may diverge here.
Fragment compounds — where the material is part of a larger natural protein — should be identified by sequence rather than by name, because the naming in this space is inconsistent between suppliers.
The short version is the first sentence; the rest is why.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.
Picking up post #24: that is the part I would want checked first.
Reframing Sequence verification slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
On post #26 — agreed on the reasoning, with one qualification.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Old habit: I write down the expected answer before I calculate it.
Post #28 is the version of this I will quote in future. One addition.
Melanocortin agonists: mechanism involves the melanocortin-4 receptor pathway that regulates appetite. The documented adverse profile includes blood pressure elevation and erections of sustained duration, the second of which is specific enough that it is the first thing worth mentioning.
The step people skip is the one I have spelled out.
Useful. I have added it to my own notes with the date on it.